Mohamad Zahedi’s Post

#Schizophrenia #Metaanalysis #Olanzapine #Plasmalevels From the article: In contrast to oral dose, our work confirmed that plasma olanzapine levels are associated with clinical response and should therefore be used to optimize treatment. https://lnkd.in/g2jj62-m

"Elafibranor significantly improves biochemical response in patients with primary biliary cholangitis (PBC) and shows anti-pruritic benefits in the phase 3 ELATIVE trial." Read the news article from our program 'Improving PBC outcomes by prioritising patient needs at https://lnkd.in/dHMidreB --- This program is made possible thanks to an independent educational grant from Ipsen. #PBC #rarediseases #PBCawareness #PBCtherapy #independentmedicaleducation #ime #continuingmedicaleducation #cme #healthcareeducation #SpringerIME

Important Results from our PHASE IB DOUBLE-BLIND RANDOMIZED CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF A NOVEL ORAL AMPHOTERICIN B FORMULATION IN HEALTHY HUMAN SUBJECTS completed in Australia. https://lnkd.in/gPmmHVvD Key Conclusions: The primary endpoint of safety and tolerability of our oral amphotercin B formulation following oral administration of both doses were met including no signs of kidney, liver and gastrointestinal (GI) toxicities of note.  In addition, the prolonged plasma half-life and increased AUC observed in this human clinical study suggests that our novel oral AmB formulation has a long circulation time which may result in the ability of the formulation to increase and sustain Amphotericin B concentrations within infected tissues without the associated GI, liver and kidney toxicity.

Today is the first day of the European Renal Association congress in Stockholm! 🇸🇪 I will be presenting our research on the development of a human renal kidney-on-a-chip to study prevention of ischemia and reperfusion injury. Using the OrganPlate, MIMETAS' complex 3D in vitro system, we can model not only ischemia but also reperfusion of the proximal tubule and perform drug screenings to identify novel therapies. In the proof-of-concept screen that I will highlight in my talk, adenosine was identified as a renoprotective agent in IRI. 💊 🗓️ Date: May 25, 2024 ⏰ Time: 08:30 - 09:45 CEST 📌 Session: moderated Orals 2.1 🏢 Location: Room T5 I'm looking forward to connecting with fellow researchers and professionals in the field of nephrology. Let’s push the boundaries of renal research together! #ERA24 #ERACongress #RenalResearch #Microfluidics #KidneyResearch #Ischemia #IRI #reperfusioninjury

🌟💊Safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 685509 We are proud to announce that our very own clinical research investigator, Friedeborg Seitz, was a key contributor to a recent study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 685509 in healthy volunteers. The study, conducted through rigorous Single Rising Dose (SRD) and Multiple Rising Dose (MRD) trials, provided valuable insights into the effects and potential of BI 685509. Highlights include: SRD Trial: 24 participants received single doses of BI 685509 or placebo, with key findings showing rapid absorption and dose-proportional exposure. MRD Trial: 60 participants received varying doses over 14–17 days, with observations of decreased orthostatic dysregulation over time and near-dose-proportional increases in exposure. The study confirmed BI 685509 was generally well tolerated, with manageable side effects. Join us in celebrating this achievement and the ongoing dedication of our team to excellence in clinical research! 👨🔬🔬 Read the full study here: https://lnkd.in/eC-6PwEd #CRS #Innovation #ClinicalResearch #PursuitofExcellence #Mannheim

😊 Collagen Daily-Benefits of Collagen peptides for the liver According to a clinical study report(patients were randomly investigated), Patients took collagen peptide, 90 out of 100 cases, albumin increased, the effective rate was 90%; In 100 cases, 92 cases of globulin decreased, the effective rate was 92%, the curative effect was very significant. 😍 A lot of practice and clinical proof, small molecule collagen peptide it can boost albumin, restore liver function, and can reverse cirrhosis and liver ascites. 😘 Hainan Huayan focus on small molecule collagen peptide over 19 years, welcome to contact us when you want to know more . #collagenpeptide #collagensupplement #collagenbenefits

Jayme Locke and a team of researchers at the University of Alabama at Birmingham have discovered that immunosuppressant’s that are FDA approved—and that are currently in use for human-to-human transplants—are the optimal choices for an immunosuppression regime for pig-to-human kidney transplants. To learn more about their research and what their hopes are for the future of xenotransplantation, read the full article below! #xenotransplantation #kidneytransplant

#Biosimilar switching is effective and safe according to research published in BioDrugs Journal: Hillel Cohen and Wolfram Bodenmueller conclude: “We believe that the available data suggest that as a scientific matter, the practice of biosimilar-to-biosimilar switching is as safe and effective as being treated solely with either a reference biologic or a single biosimilar, or the switch from a reference biologic to its biosimilar. Any suggestions to the contrary are not supported by clinical evidence or the underlying science.” https://lnkd.in/eFQmW_qS

Exciting news! Our colleagues Sonnal L. (ESR5) and Emmanouil Mavrogeorgis (ESR3) published a research article on "Exploratory Study Analyzing the Urinary Peptidome of T2DM Patients Suggests Changes in ECM but Also Inflammatory and Metabolic Pathways Following GLP-1R Agonist Treatment." Head over to https://lnkd.in/euZehQru to read the full article now! • Type II diabetes mellitus (T2DM) accounts for about 90% of all diabetes cases worldwide, emphasizing the critical need for effective management and treatment strategies. • The GLP-1R agonists have shown promise in targeting six core defects associated with T2DM, opening avenues for understanding and potentially revolutionizing T2DM treatment, even though the exact molecular mechanisms remain partially unknown. • The exploratory study leveraged CE-MS analysis of urine samples from 32 T2DM patients, both pre- and post-treatment with GLP-1R agonist drugs, to delve deep into the molecular impacts of the treatment. • The research utilized data from the PROVALID study, a prospective cohort study focused on validating biomarkers in T2DM patients, providing a robust framework for the research. • The study identified significant changes in 70 urinary peptides derived from 26 different proteins, shedding light on the substantial effects of GLP-1R agonist treatment on the urinary peptidome. • The downregulation of several peptides associated with insulin resistance and inflammation suggests potential molecular pathways through which GLP-1R agonists can manage T2DM and possibly prevent or delay the progression of related diseases. #T2DMManagement, #GLP1RAgonists, #MolecularMechanisms, #PROVALIDStudy, #UrinaryPeptidome, #DiabetesResearch, #MedicalResearch #ScienceCommunity #Diet #Food #CKD #STRATEGYCKD #mariecurie #Horizon2020